Atossa Therapeutics' COVID-19 Nasal Spray Safe In Early-Stage Study

by Vandana Singh, Benzinga Editor

February 25, 2021 11:15 AM | 1 min read

Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19.
The treatment was considered to be safe and well-tolerated at two different dose levels over 14 days.
The final analysis indicates that there were no serious adverse events, no discontinuations, no bronchospasm.
Only one of the 32 subjects in the study experienced moderate adverse events, and all other adverse events were considered mild.
An additional pre-clinical study is expected to start this quarter.
Price Action: ATOS surged 8.6% at $3.02 on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care FDA General Covid-19 Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.